Category: Buzz

Blog

Market Buzz: $ICNB #IconicBrands @IconicBrandsUSA – Some say .30? Really?

Maybe in her prime Christie Brinkley could push a penny stock above a few cents. Here’s the buzz being floated over and over on Iconic Brands Inc. (Pink Sheets: ICNB).  This company, that last filed a 10 of any kind in 2013, has Christie Brinkley in her Instagram feed being repeated all over IHub. That’s not the Company’s doing, but the fans believe all and make extraordinary claims which make MILLIONS of shares trade.  Here’s the one that stands out:  The link included goes to this post: Really – this is all fluff, as this company is non-reporting.  My prediction:

Most Talked About: $AMRN $BIEL $FNMA $TBEV $ICNB $NWBO $SGBY $SPCL $SFOR $WMIH – For Monday, September 12, 2016

Most Talked About:  AMRN Amarin Corp. PLC ADS BIEL Bioelectronics Corp. FNMA Fannie Mae TBEV High Performance Beverages Comp. ICNB Iconic Brands Inc. NWBO NorthWest Biotherapeutics SGBY Signal Bay Inc. SPCL Solaris Power Cells Inc. SFOR StrikeForce Technologies, Inc. WMIH WMIH Corp. .. Latest News:   FNMA Court Throws Out Another Lawsuit Over Fannie and Freddie Profits at The Wall Street Journal Fri 4:25pm WMIH WMIH CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits at EDGAR Online Fri 4:18pm NWBO NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Eq

FYI – Canada’s #FamilyDay Bank & Brokerage Holiday Schedule – BC Banks go a Week Early!

Remember: Banking Holidays & Stock Market Holidays are Often Different Stock Market Holiday Schedule: Bank Holiday Schedule: US Stock Markets   Canadian Stock Markets US Banks   Canadian Banks Canada’s Family Day Holiday is different for BANKS and BROKERAGES – BUT only in BC! All brokers and exchanges take the holiday as February 15th.  In British Columbia, BANKS ONLY take the holiday on February 8th.  All other provinces have their BANK holiday the same as BROKERS, February 15th.      Complicated? Yes… But here is that BANK SCHEDULE and how it breaks out:    February 8 Monday Family Day Provincial

The Buzz on $AVXL – #Anavex – Investigation, Discovery & Shareholders!

I’m sure you all know that we have covered Anavex Holdings $AVXL since at least May. Likely before most of you ever heard of it. We’ve never held a position and we’ve never been compensated. We followed it for the upside we saw, as this stock was heavily promoted. Now, we see the downside as kicking in. Don’t be left holding here, if you value your investment.    The Buzz on Twitter:  [cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] Profit Trade Room ‏@ProfitTradeRoom  $AVXL oops, told you this stock is crash and short is the only right thing to do! Hope you’ll listen

The Buzz on Finjan Holdings, Inc. $FNJN as Share Price Sinks Below $1

Finjan Holdings, Inc. (NasdaqCM: FNJN) are slipping below $1 after being up in the first minutes of trading. Here is the Buzz on FNJN:       cjboro ‏@beach_trades  $FNJN Adding .96-8     cjboro ‏@beach_trades  $SEED $FNJN $NNVC $VGZ #SmallCapswings large and all green in this tape. Don’t tell me no small cap swings- Just need reason/theme/catalyst     UglyAmerican ‏@TheUglyAmerikan @beach_trades @laserarchive @symantec $FNJN has strong ties to $CSCO, ex CEO is board member @CybeRisk_Sec are former execs as well View conversation       cjboro ‏@beach_trades  $FNJN Finjan 2/8 and the Source Capital Group’s 2016 Disruptive Growth

News $BABY – #Natus Medical Announces 2016 Annual and First Quarter Financial Guidance

Updates Fourth Quarter 2015 Revenue Announces Fourth Quarter 2015 Financial Results Conference Call Date PLEASANTON, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) — Natus Medical Incorporated (NASDAQ:BABY) today announced its financial guidance for the first quarter and full year 2016. For the full year 2016, the Company expects to report revenue of $445 million to $450 million and non-GAAP earnings per share of $1.84 to $1.88. For the first quarter of 2016, the Company expects to report revenue of $96.5 million to $97.5 million and non-GAAP earnings per share of $0.34 to $0.35, an increase of 10% to 13% over the

Buzz

Huge News $AVXL – #Anavex Announces Positive Dose-Response Data for ANAVEX 2-73 in Alzheimer’s Disease Patients

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] NEW YORK, Jan. 11, 2016 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported a positive dose-response relationship has been observed in a pre-planned interim analysis of data from the ongoing Phase 2a trial of ANAVEX 2-73 for treatment of mild to moderate Alzheimer’s disease. The change in Mini Mental State Examination score (MMSE-Δ) (MMSE difference recorded for every single study subject

News $CYCC $CYCCP – #Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016

BERKELEY HEIGHTS, N.J., Jan. 11, 2016 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today reviewed 2015 achievements and provided an outline of the Company’s key business objectives for 2016.  These will be highlighted at the Company’s presentation during the Biotech Showcase™ 2016 Conference at 9:30 a.m. PST, Monday, January 11, 2016, at the Parc 55 Wyndham Hotel – Union Square at 55 Cyril Magnin Street in San Francisco. “During 2015, we continued to follow-up patients in SEAMLESS, our Phase 3 clinical trial evaluating sapacitabine in the front-line treatment setting of elderly patients with acute myeloid

News: Coherus $CHRS and Baxalta $BLXT Announce CHS-0214 (Investigational Etanercept Biosimilar) Met Primary Efficacy Endpoint in Phase 3 Rheumatoid Arthritis Clinical Study (RaPsODY)

REDWOOD CITY, Calif., and BANNOCKBURN, Ill., Jan. 11, 2016 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (NASDAQ:CHRS) and Baxalta Incorporated (NYSE:BXLT) today announced that CHS-0214, a proposed biosimilar of Enbrel® (etanercept), met its primary endpoint in a confirmatory, double-blind, randomized, controlled, two-part clinical study. This ongoing study is evaluating the efficacy and safety of CHS-0214 compared to Enbrel in patients with moderate-to-severe rheumatoid arthritis that is inadequately controlled with methotrexate alone. The study continues as planned until Week 52. The primary efficacy endpoint was the proportion of subjects achieving ACR20 (20% improvement according to the American College of Rheumatology criteria) at Week 24. The primary endpoint was within

Buzz

News $NEON – #Neonode Reports on a Successful Week at the 2016 CES in Las Vegas

STOCKHOLM, Sweden, Jan. 11, 2016 (GLOBE NEWSWIRE) — Neonode Inc. (NASDAQ:NEON), the Optical Interactive Sensing Technology Company, reports on a successful week at the 2016 CES in Las Vegas. Neonode’s technology was on display at the Encore Hotel, in the ST Micro Private suites, at the Autoliv autonomous driving demonstration, and the Volvo booth at the CES Central Hall. The big theme for the 2016 CES was autonomous driving enablement technology, and Neonode demonstrated leadership in this space with its steering wheel technology, zForce DRIVE™. Neonode also solidified its position as key a innovator and contributor in the automotive segment

News $ETX #TSX – #Etrion to Present at Pareto Securities Power and Renewable Energy Conference

January 11, 2016, Geneva, Switzerland – Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX / OMX: ETX), a solar independent power producer, announces that the Company’s CEO, Marco A. Northland, will be presenting at the Pareto Securities Power and Renewable Energy Conference in Oslo on Thursday, January 14, 2016, at 2:35pm Central European Time. A copy of the presentation will be available on Etrion’s website at www.etrion.com. About Etrion Etrion Corporation is an independent power producer that develops, builds, owns and operates utility-scale solar power generation plants. The Company owns 139 MW of installed solar capacity in Italy, Chile and

News $FXCM and #PFSOFT Announce New Partnership

LONDON, Jan. 11, 2016 (GLOBE NEWSWIRE) — FXCM Inc. (NYSE:FXCM), a leading online provider of foreign exchange, or FX, trading and related services, today announced its partnership with PFSOFT, a developer of professional trading software for banks, prime brokers and retail brokers. FXCM will provide trade execution and market data to the PFSOFT Protrader multi-asset solution through FIX API.  Striving to create an exceptional solution, PFSOFT has integrated FXCM’s FIX API, which offers both FX and CFD execution. As a result of this collaboration every broker who uses the Protrader solution will be able to access FXCM’s unique capabilities in both FX and CFD performance. “PFSOFT is

News: #Sizzix Previews Newest Inspiring Products for DIY Market

Premier crafts brand introduces exciting additions at industry trade show LAKE FOREST, Calif. (PRWEB) January 10, 2016 Continuing to offer creative consumer options for the crafts market, Sizzix® previewed its newest die-cutting, embossing and accessory products at the Craft and Hobby Association (CHA) 2016 Mega Show in Anaheim, Calif. The latest products to join the Sizzix family include: Lightweight and stable, the Big Shot™ Tool Caddy is the smart storage solution for any Big Shot or Big Shot Express Machine. This handy snap-on accessory easily organizes cutting pads and platforms with its adjustable sliders, boasts a built-in tape dispenser, while

News Innovative New #Novo34 Software Fills the “Technology” Void in the World of Financial Investments

Novo34 adopts a hi-tech approach to finance and accounting (PRWEB) January 10, 2016 Since the advent of the ATM, the credit card, and online banking, not much in the way of innovation has come out of the financial sector. Even though attempts to improve the “everyday” experience from the standpoint of the consumer have had tangible success, the daily routine of the finance professional remains largely unaltered. The financial industry is faced with a set of challenges that makes finding solutions grounded in technology exceptionally difficult. It isn’t surprising that nearly 7 years since the aftermath of the financial crisis,

News $ABUS – $Arbutus Provides a Corporate Update and Outlines 2016 Milestones

Phase II Multidose Study of ARB-1467 in HBV Patients Was Initiated in 2015  Phase II Single Dose HBsAg Reduction Data Expected in 3Q16 Four HBV Products in Clinical Development by Year-End   VANCOUVER, British Columbia and DOYLESTOWN, Pa., Jan. 10, 2016 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today issued an update on recent company progress as well as a review of expected 2016 milestones. “2015 was a very important year for Arbutus as we transitioned into a  focused HBV therapeutic solutions company,

News $NSTG – #NanoString Technologies Provides Preliminary Operational and Financial Results for 2015

SEATTLE, Jan. 10, 2016 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today provided preliminary operational and financial results for the year ended December 31, 2015. Financial Highlights: Total revenue for 2015 expected to be in the range of $61.5 to $62.5 million, representing an increase of 29% to 31% over 2014, versus prior guidance of $60.0 to $63.0 million Total revenue for the fourth quarter of 2015 expected to be in the range of $21.1 to $22.1 million, representing an increase of 35% to 42% over the

News $ABUS – #Arbutus Provides a Corporate Update and Outlines 2016 Milestones

Phase II Multidose Study of ARB-1467 in HBV Patients Was Initiated in 2015  Phase II Single Dose HBsAg Reduction Data Expected in 3Q16 Four HBV Products in Clinical Development by Year-End   VANCOUVER, British Columbia and DOYLESTOWN, Pa., Jan. 10, 2016 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today issued an update on recent company progress as well as a review of expected 2016 milestones. “2015 was a very important year for Arbutus as we transitioned into a  focused HBV therapeutic solutions company,

News $BID – #Sotheby’s Conference Call Invitation

NEW YORK, Jan. 10, 2016 (GLOBE NEWSWIRE) — Sotheby’s (NYSE:BID) will be holding an analyst and investor conference call on Monday, 11 January 2016 at 9:00 AM EST.  The call will be hosted by Tad Smith, President and Chief Executive Officer, and Dennis Weibling, Interim Chief Financial Officer.  The call will consist of a brief discussion by the Company followed by a question and answer period.  Domestic callers should dial 888-371-8897 and international callers should dial 970-315-0479.  The call reservation number is 23802472.  Please establish a line approximately 10 minutes prior to the scheduled start of the call. To listen

News – @DalianWanda @weinsteinfilms – OBH the Host Site of Golden Globe Parties

LOS ANGELES, Jan. 10, 2016 (GLOBE NEWSWIRE) — On Sunday, January 10, One Beverly Hills of the Wanda Group will be the host site for the Weinstein Company – Netflix and Fox Studio Golden Globes after parties.  The 8-acre site is being transformed with two pavilions totaling 32,000 square feet of space for their Golden Globe nominees and friends.  One Beverly Hills is the future home of luxury residences and hotel designed by Richard Meier & Partners Architects.  One Beverly Hills is Wanda’s flagship property in the western United States. Acquired by Wanda in 2014, the highly diversified company has

News $CYTK – #Cytokinetics Presents Analyses Demonstrating Predictive Value of Slow Vital Capacity for Clinical Outcomes in ALS

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2016 (GLOBE NEWSWIRE) — Cytokinetics, Inc. (Nasdaq:CYTK) today announced the presentation of exploratory analyses of data from EMPOWER, a Phase 3 clinical trial of dexpramipexole in patients with ALS, which demonstrated the rate of decline of slow vital capacity (SVC) predicts the risk of meaningful clinical events, including a decline in the three respiratory questions of the ALSFRS-R, as well as the time to the first occurrence of respiratory insufficiency, tracheostomy or death.  Data from placebo-treated patients in EMPOWER were provided to Cytokinetics by Knopp Biosciences.  The analyses were presented recently at the 6th